NCT00940368

Brief Summary

Ginger root powder is found to be significantly effective,when given as an add-on therapy in reducing chemotherapy induced nausea and vomiting in children and adolescents receiving chemotherapy. It is very cost effective and as compared to the other add-on therapy drug like aprepitant.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jun 2009

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 15, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 16, 2009

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2010

Completed
Last Updated

July 28, 2009

Status Verified

July 1, 2009

Enrollment Period

6 months

First QC Date

July 15, 2009

Last Update Submit

July 24, 2009

Conditions

Keywords

NauseaVomitingChemotherapy

Outcome Measures

Primary Outcomes (1)

  • Reduction in the Incidence and Severity of Chemotherapy Induced Nausea and Vomiting

    6 months

Study Arms (2)

Ginger arm

EXPERIMENTAL

The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A: Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day

Dietary Supplement: Provision of capsules containing ginger powder or placebo

Placebo arm

PLACEBO COMPARATOR

Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B: Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day

Dietary Supplement: Provision of capsules containing ginger powder or placebo

Interventions

The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy. For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram. For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.

Also known as: Tulsi Ayurvedic Products & Research(P)LTd,U.P.,India
Ginger armPlacebo arm

Eligibility Criteria

Age8 Years - 21 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • All patients must have a histologically confirmed diagnosis of Osteosarcoma/ Malignant Fibrohistiocytoma of bone that is currently being treated with chemotherapy with high emetogenic potential chemotherapeutic agent(Cisplatin at a dose 120mg/m2 ; Adriamycin 75 mg/m2)
  • Age group : 8-21 yrs.
  • Weight : greater than or equal to 20 kg and less than 40 kg in Category 1
  • Weight : greater than or equal to 40 kg and less than 60 kg in Category 2
  • Patients who are willing to participate in study.
  • Patients or their parents who can understand Hindi or English.

You may not qualify if:

  • Patients of age \<8 yrs or age \>21 yrs.
  • Weight \< 20 kg and greater than or equal to 40 kg in Category 1
  • Weight \< 40 kg and greater than or equal to 60 kg in Category 2
  • Patients receiving chemotherapy with drugs other than Cisplatin.
  • Patients receiving a dosage of chemotherapy with Cisplatin\<120 mg/m2.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dr. B.R. Ambedkar Institute Rotary Cancer Hospital

New Delhi, National Capital Territory of Delhi, 110049, India

RECRUITING

Related Publications (1)

  • Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer. 2011 Feb;56(2):234-8. doi: 10.1002/pbc.22778. Epub 2010 Sep 14.

MeSH Terms

Conditions

NauseaVomiting

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Anu K, BSc.Nursing

    All India Institute of Medical Sciences

    PRINCIPAL INVESTIGATOR
  • Kamlesh K Sharma, MSc.Nursing

    All India Institute of Medical Sciences

    STUDY DIRECTOR
  • Sameer Bakhshi, MD

    All India Institute of Medical Sciences

    STUDY CHAIR
  • Y K Gupta, MD,FAMS,FIPS

    All India Institute of Medical Sciences

    STUDY CHAIR

Central Study Contacts

Anu K, BScNursing

CONTACT

Kamlesh K Sharma, MScNursing

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 15, 2009

First Posted

July 16, 2009

Study Start

June 1, 2009

Primary Completion

December 1, 2009

Study Completion

January 1, 2010

Last Updated

July 28, 2009

Record last verified: 2009-07

Locations